GPC6-AS1

Across TCGA pan-cancer cohorts, GPC6-AS1 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated GPC6-AS1 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher GPC6-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPC6-AS1 expression acts as an unfavorable survival marker, although some lineages such as PAAD and ESCA show a favorable association.

CHOL, PAAD, and SKCM are the cancer types where GPC6-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	All	0.106	0.528	.005	63	view →
PAAD	DFS	Tertile	All	0.428	0.238	.003	60	view →
SKCM	OS	Tertile	II,III,IV	0.230	0.417	.011	36	view →
SARC	OS	Tertile	All	0.729	0.915	.001	22	view →
ESCA	OS	Tertile	II,III,IV	0.633	0.357	.012	16	view →
PCPG	DFS	Tertile	All	0.837	0.935	.023	15	view →
BLCA	DFS	Tertile	III,IV	0.121	0.488	.029	9	view →
CESC	OS	Tertile	All	0.690	0.881	.035	6	view →
LGG	OS	Median	All	0.929	0.854	.020	5	view →
KIRP	DFS	Tertile	III,IV	0.818	0.488	.039	2	view →
LIHC	OS	Median	All	0.564	0.745	.015	2	view →
KIRC	OS	Tertile	II,III,IV	0.393	0.609	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

GPC6-AS1–CHOL (DFS)

Open the CHOL breakdown →